Ono Pharmaceutical Co Ltd 2019 SR
The report outlines ONO PHARMACEUTICAL's CSR strategy, focusing on its 'ECO VISION 2050' and materiality issues like innovative drug discovery and climate change. Key highlights include the company's commitment to reducing Scope 1 and 2 emissions by 50% by 2030 and achieving net-zero by 2050. It details social initiatives such as the 'ONO SWITCH Project' for medical donations and the 'Healthy Body Campaign' for disaster recovery. The report also highlights the company's inclusion in the FTSE4Good Index and its 'A' rating from CDP for climate change.
Company: Ono Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2019
Type: SR
Pages: 85
Ono Pharmaceutical Co Ltd
CSR Report
The report outlines ONO PHARMACEUTICAL's CSR strategy, focusing on its 'ECO VISION 2050' and materiality issues like innovative drug discovery and climate change. Key highlights include the company's commitment to reducing Scope 1 and 2 emissions by 50% by 2030 and achieving net-zero by 2050. It details social initiatives such as the 'ONO SWITCH Project' for medical donations and the 'Healthy Body Campaign' for disaster recovery. The report also highlights the company's inclusion in the FTSE4Good Index and its 'A' rating from CDP for climate change.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2018
Published
Sep 1, 2019
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Net Zero Target
Employees